Arrowhead Pharmaceuticals, Inc. (ARWR) Technical Analysis
$42.40▲0.21%
Market is closed - opens 8 PM, 03 Nov 2025
Insights
- Arrowhead Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Arrowhead Pharmaceuticals stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Arrowhead Pharmaceuticals stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Arrowhead Pharmaceuticals stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 74.27 | Sell |
Stochastic | 85.68, 88.83 | Sell |
Ultimate Oscillator | 57.96 | Neutral |
Stochastic Relative Strength Index | 89.13, 72.47 | Neutral |
Moving Average Convergence Divergence | 2.44, 2.32 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.35 | Buy |
20 | 38.11 | Buy |
50 | 32.61 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.77 | Buy |
20 | 38.0 | Buy |
50 | 33.08 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.43 | Buy |
20 | 38.2 | Buy |
50 | 31.52 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 41.53 | Buy |
20 | 41.29 | Buy |
50 | 40.08 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 41.94 | Buy |
20 | 41.22 | Sell |
50 | 42.24 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 47.49 |
Resistance L2 | 45.41 |
Resistance L1 | 43.86 |
Pivot Point | 41.78 |
Support L1 | 40.23 |
Support L2 | 38.15 |
Support L3 | 36.6 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.